  In multi-stage radiotherapy, a patient is treated in several stages separated
by weeks or months. This regimen has been motivated mostly by radiobiological
considerations, but also provides an approach to reduce normal tissue dose by
exploiting tumor shrinkage. The paper considers the optimal design of
multi-stage treatments, motivated by the clinical management of large liver
tumors for which normal liver dose constraints prohibit the administration of
an ablative radiation dose in a single treatment.
  We introduce a dynamic tumor model that incorporates three factors: radiation
induced cell kill, tumor shrinkage, and tumor cell repopulation. The design of
multi-stage radiotherapy is formulated as a mathematical optimization problem
in which the total dose to the liver is minimized, subject to delivering the
prescribed dose to the tumor. Based on the model, we gain insight into the
optimal administration of radiation over time, i.e. the optimal treatment gaps
and dose levels.
  We analyze treatments consisting of two stages in detail. The analysis
confirms the intuition that the second stage should be delivered just before
the tumor size reaches a minimum and repopulation overcompensates shrinking.
Furthermore, it was found that, for a large range of model parameters,
approximately one third of the dose should be delivered in the first stage. The
projected benefit of multi-stage treatments depends on model assumptions.
However, the model predicts large liver dose reductions by more than a factor
of two for plausible model parameters.
  The analysis of the tumor model suggests that substantial reduction in normal
tissue dose can be achieved by exploiting tumor shrinkage via an optimal design
of multi-stage treatments. This suggests taking a fresh look at multi-stage
radiotherapy for selected disease sites where substantial tumor regression
translates into reduced target volumes.
